GlassScriptPhysician profile
Rodney D Gin
NPI 1851584015
$6,267.07
in general payments reported to CMS, 2019-2025
24 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $597 · 2021: $1,424 · 2022: $1,274 · 2023: $1,142 · 2024: $766 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,615 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,596.14 | 2019-2025 | |
| Genzyme Corporation | $1,085.94 | 2019-2025 | |
| Leo Pharma INC. | $617.81 | 2021-2023 | Adbry |
| Janssen Biotech, INC. | $418.97 | 2020-2023 | Simponi Aria, Remicade, Stelara |
| Allergan, INC. | $397.30 | 2021-2023 | |
| Incyte Corporation | $351.69 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $332.38 | 2020-2024 | Absorica Ld, Winlevi |
| Almirall LLC | $183.35 | 2019-2023 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $168.71 | 2019-2021 | |
| Biofrontera INC. | $161.06 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $146.65 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $145.27 | 2020-2025 | Dupixent |
| Lilly USA, LLC | $122.96 | 2019-2021 | |
| Merz North America, INC. | $121.62 | 2020-2023 | Xeomin |
| Galderma Laboratories, L.P. | $71.83 | 2021-2025 | Dysport |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $70.25 | 2020-2021 | |
| Dermira, INC. | $52.88 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $49.23 | 2021 | |
| Ucb, INC. | $46.17 | 2023 | Bimzelx |
| Revance Therapeutics, INC. | $40.72 | 2024 | Daxxify |
| Pfizer INC. | $28.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.83 | 2025 | |
| Mayne Pharma Commercial LLC | $24.40 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $6.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Gin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.